Patents by Inventor Marcin KOWANETZ
Marcin KOWANETZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240033370Abstract: The invention provides immunoconjugates of Formula I comprising an anti-PD-L1 antibody linked by conjugation to one or more 8-Cyc-2-aminobenzazepine derivatives. The invention also provides 8-Cyc-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.Type: ApplicationFiled: December 10, 2021Publication date: February 1, 2024Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Shelley Erin ACKERMAN, Michael N. ALONSO, David DORNAN, Marcin KOWANETZ, Romas KUDIRKA, Arthur LEE, William MALLET, Brian SAFINA, Matthew ZHOU
-
Publication number: 20230159641Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.Type: ApplicationFiled: November 21, 2022Publication date: May 25, 2023Inventors: Marcin KOWANETZ, Hartmut KOEPPEN, Zachary BOYD, Zhiming LIAO, Yifei ZHU, Bharathi VENNAPUSA, Patrick C. ROCHE
-
Publication number: 20230086603Abstract: The invention relates to programmed death-ligand 1 (PD-L1) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of producing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods for enhancing or reducing or inhibiting an immune response in a mammal.Type: ApplicationFiled: January 21, 2021Publication date: March 23, 2023Applicant: BOLT BIOTHERAPEUTICS, INCInventors: Michael N. ALONSO, David DORNAN, Karla HENNING, Justin KENKEL, Marcin KOWANETZ, Heidi LEBLANC, William MALLET
-
Publication number: 20230069055Abstract: The invention relates to programmed death-ligand 1 (PD-L1) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of producing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods for enhancing or reducing or inhibiting an immune response in a mammal.Type: ApplicationFiled: January 21, 2021Publication date: March 2, 2023Applicant: BOLT BIOTHERAPEUTICS, INCInventors: Michael N. ALONSO, David DORNAN, Karla HENNING, Justin KENKEL, Marcin KOWANETZ, Heidi LEBLANC, William MALLET
-
Publication number: 20220412981Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g.Type: ApplicationFiled: March 4, 2022Publication date: December 29, 2022Inventors: David FABRIZIO, Garrett M. FRAMPTON, Priti HEGDE, Marcin KOWANETZ, David SHAMES, Philip J. STEPHENS, James Xin SUN, Roman YELENSKY, Wei ZOU
-
Patent number: 11535671Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.Type: GrantFiled: October 17, 2019Date of Patent: December 27, 2022Assignee: Genentech, Inc.Inventors: Priti Hegde, Marcin Kowanetz, Gregg Fine, Sanjeev Mariathasan, Richard Bourgon
-
Patent number: 11530269Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.Type: GrantFiled: May 11, 2020Date of Patent: December 20, 2022Assignee: Ventana Medical Systems, Inc.Inventors: Marcin Kowanetz, Hartmut Koeppen, Zachary Boyd, Zhiming Liao, Yifei Zhu, Bharathi Vennapusa, Patrick C. Roche
-
Publication number: 20220363764Abstract: Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.Type: ApplicationFiled: March 4, 2022Publication date: November 17, 2022Inventors: Daniel Shin-Yu CHEN, Priti HEGDE, Hartmut KOEPPEN, Marcin KOWANETZ
-
Publication number: 20220195066Abstract: The invention provides immunoconjugates of Formula I comprising an anti-CEA antibody linked by conjugation to one or more 8-Het-2-aminobenzazepine derivatives. The invention also provides 8-Het-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.Type: ApplicationFiled: December 9, 2021Publication date: June 23, 2022Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Marcin Kowanetz, Romas Kudirka, Arthur Lee, William Mallet, Brian Safina, Matthew Zhou
-
Publication number: 20220152215Abstract: The invention provides an immunoconjugate of formula (I) or (II) Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds carcinoembryonic antigen (“CEA”) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.Type: ApplicationFiled: March 13, 2020Publication date: May 19, 2022Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior UniversityInventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Marcin Kowanetz, Romas Kudirka, Arthur Lee, William Mallet, Brian Safina, Matthew Zhou, Edgar George Engleman
-
Publication number: 20220146517Abstract: Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.Type: ApplicationFiled: August 16, 2021Publication date: May 12, 2022Inventors: Marcin KOWANETZ, Daniel Shin-Yu CHEN, Hartmut KOEPPEN
-
Patent number: 11299544Abstract: Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.Type: GrantFiled: September 10, 2015Date of Patent: April 12, 2022Assignee: Genentech, Inc.Inventors: Daniel Shin-Yu Chen, Priti Hegde, Hartmut Koeppen, Marcin Kowanetz
-
Patent number: 11300570Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g.Type: GrantFiled: April 1, 2019Date of Patent: April 12, 2022Assignees: Genentech, Inc., Foundation Medicine, Inc.Inventors: David Fabrizio, Garrett M. Frampton, Priti Hegde, Marcin Kowanetz, David Shames, Philip J. Stephens, James Xin Sun, Roman Yelensky, Wei Zou
-
Publication number: 20220073623Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, non-small cell lung cancer (NSCLC). The invention provides methods of treating NSCLC, methods of determining whether a patient suffering from NSCLC is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from NSCLC to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from NSCLC, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor cells and/or tumor-infiltrating immune cells).Type: ApplicationFiled: November 26, 2021Publication date: March 10, 2022Inventor: Marcin KOWANETZ
-
Patent number: 11254987Abstract: This invention provides methods for the treatment of cancer in subjects having medium or low methylation level in the PD-L1 promoter region. Also provided are related kits and articles of manufacture.Type: GrantFiled: November 22, 2017Date of Patent: February 22, 2022Assignee: GENENTECH, INC.Inventors: Edward Kadel, Marcin Kowanetz, Kimberly Walter
-
Publication number: 20210140967Abstract: Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.Type: ApplicationFiled: January 14, 2021Publication date: May 13, 2021Inventors: Marcin KOWANETZ, Daniel Shin-Yu CHEN, Hartmut KOEPPEN
-
Publication number: 20200333348Abstract: Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.Type: ApplicationFiled: May 20, 2020Publication date: October 22, 2020Inventors: Marcin KOWANETZ, Daniel Shin-Yu CHEN, Hartmut KOEPPEN
-
Publication number: 20200270348Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.Type: ApplicationFiled: May 11, 2020Publication date: August 27, 2020Inventors: Marcin KOWANETZ, Hartmut KOEPPEN, Zachary BOYD, Zhiming LIAO, Yifei ZHU, Bharathi VENNAPUSA, Patrick C. ROCHE
-
Patent number: 10689445Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.Type: GrantFiled: October 6, 2017Date of Patent: June 23, 2020Assignees: Ventana Medical Systems, Inc., Spring BioScience CorporationInventors: Marcin Kowanetz, Hartmut Koeppen, Zachary Boyd, Zhiming Liao, Yifei Zhu, Bharathi Vennapusa, Patrick C. Roche
-
Publication number: 20200157635Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer. The invention is based, at least in part, on the discovery that an immune-score expression level based on one or more of PD-L1, CXCL9, IFNG, GZMB, CD8A, and PD-1 in a sample obtained from an individual having cancer can be used in methods of predicting the therapeutic efficacy of treatment with a PD-L1 axis binding antagonist (e.g., a PD-L1 binding antagonist (e.g., anti-PD-L1 antibody, e.g., atezolizumab (MPDL3280A)) or a PD-1 binding antagonist (e.g., anti-PD-1 antibody)).Type: ApplicationFiled: October 3, 2019Publication date: May 21, 2020Inventors: Marcin KOWANETZ, Mahrukh HUSENI, Wei ZOU